ALDAGEN

ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.

#People #Financial #Website #More

ALDAGEN

Social Links:

Facebook

Industry:

Biotechnology Health Care Therapeutics

Founded:

2000-01-01

Address:

Durham, North Carolina, United States

Country:

United States

Website Url:

http://www.aldagen.com

Total Employee:

11+

Status:

Active

Contact:

919-484-2571

Email Addresses:

[email protected]

Total Funding:

64.53 M USD

Technology used in webpage:

Domain Not Resolving Black Lotus NameSilo DNS BuyVM

Current Advisors List

chris-kroeger_image

Chris Kroeger Board of Observer @ Aldagen
Board_observer

Current Employees Featured

not_available_image

Tom Amick
Tom Amick CEO and Chairman @ Aldagen
CEO and Chairman

not_available_image

Andrew E. Balber
Andrew E. Balber Founder and CSO @ Aldagen
Founder and CSO

Founder

not_available_image

Andrew E. Balber

Investors List

the-aurora-funds_image

Official Site Inspections

http://www.aldagen.com

Host Informations
Whois Informations

Loading ...